Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $14.60 Consensus PT from Brokerages

Posted by Defense World Staff on Sep 25th, 2023

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) has been given a consensus rating of “Buy” by the six research firms that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $14.60.

RVPH has been the topic of a number of research analyst reports. Roth Mkm initiated coverage on Reviva Pharmaceuticals in a research note on Wednesday, September 20th. They issued a “buy” rating and a $12.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Reviva Pharmaceuticals in a research note on Wednesday, August 16th. Roth Capital reissued a “buy” rating on shares of Reviva Pharmaceuticals in a research note on Wednesday, September 20th. Finally, Benchmark initiated coverage on Reviva Pharmaceuticals in a research note on Thursday, June 8th. They issued a “buy” rating and a $17.00 target price on the stock.

Get Our Latest Report on RVPH

Reviva Pharmaceuticals Stock Performance

Shares of RVPH stock opened at $4.90 on Friday. Reviva Pharmaceuticals has a 52-week low of $1.56 and a 52-week high of $9.25. The company has a market capitalization of $110.99 million, a PE ratio of -3.48 and a beta of 0.11. The business’s fifty day moving average is $4.53 and its 200 day moving average is $5.34.

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) last issued its quarterly earnings data on Monday, August 14th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.26). On average, sell-side analysts forecast that Reviva Pharmaceuticals will post -1.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN grew its stake in shares of Reviva Pharmaceuticals by 4,550.0% during the second quarter. Wells Fargo & Company MN now owns 5,115 shares of the company’s stock valued at $30,000 after buying an additional 5,005 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Reviva Pharmaceuticals by 5.9% during the second quarter. BlackRock Inc. now owns 90,006 shares of the company’s stock worth $527,000 after purchasing an additional 5,052 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Reviva Pharmaceuticals by 3.8% during the second quarter. Geode Capital Management LLC now owns 150,949 shares of the company’s stock worth $885,000 after purchasing an additional 5,519 shares during the period. Wolverine Asset Management LLC boosted its holdings in shares of Reviva Pharmaceuticals by 137.6% during the second quarter. Wolverine Asset Management LLC now owns 14,501 shares of the company’s stock worth $85,000 after purchasing an additional 8,397 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Reviva Pharmaceuticals by 631.3% during the second quarter. Tower Research Capital LLC TRC now owns 11,109 shares of the company’s stock worth $65,000 after purchasing an additional 9,590 shares during the period. 24.09% of the stock is owned by institutional investors.

Reviva Pharmaceuticals Company Profile

(Get Free Report

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.